Go Deep
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,520 | -4.7 | 1.68 | 0.10 | 1,177.09 |
| Oct 2026 | 19,578 | -4.6 | 1.65 | 0.10 | 1,158.36 |
| Oct 2026 | 19,335 | -5.0 | 1.74 | 0.10 | 1,222.15 |
| Oct 2026 | 19,600 | -4.7 | 1.65 | 0.10 | 1,149.84 |
| Oct 2026 | 19,546 | -4.7 | 1.67 | 0.10 | 1,165.29 |
| Oct 2026 | 19,251 | -5.0 | 1.77 | 0.10 | 1,242.09 |
| Oct 2026 | 19,426 | -4.9 | 1.71 | 0.10 | 1,193.63 |
| Oct 2026 | 19,706 | -4.5 | 1.61 | 0.10 | 1,118.53 |
4D Molecular Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,781,000.0 | 3,047,000.0 | 85,090,000.0 | 90,000.0 |
| Net Profit | -72,936,000.0 | -68,760,000.0 | 19,397,000.0 | -56,876,000.0 |
| EPS | -1.0 | -1.0 | — | -1.0 |
4D Molecular Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 85,209,000.0 | 37,000.0 | 20,723,000.0 | 3,129,000.0 |
| Net Profit | -140,109,000.0 | -160,868,000.0 | -100,837,000.0 | -107,494,000.0 |
| EPS | -2.4 | -3.0 | -2.6 | -3.3 |
4D Molecular Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 566,711,000.0 | 560,384,000.0 | 339,891,000.0 | 261,846,000.0 | — |
| Total Liabilities | 61,047,000.0 | 49,778,000.0 | 32,062,000.0 | 30,509,000.0 | — |
| Total Equity | 505,664,000.0 | 510,606,000.0 | 307,829,000.0 | 231,337,000.0 | — |
Owes vs Owns
4D Molecular Therapeutics, Inc. owed $0.17 for every $1 it owned in Jun 2026, up from $0.12 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.11× | 0.09× | 0.09× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
4D Molecular Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 71.1%Fixed assets (tangible) 5.8%Long-term investments 19.7%Other assets 3.5%
How it's funded — Dec 2025
Short-term debt 1.0%Long-term debt 2.8%Payables 2.0%Other liabilities 5.0%Shareholders' equity 89.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 402.7 | 424.9 | 288.2 | 213.6 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 33.0 | 40.6 | 31.7 | 35.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 111.4 | 80.6 | 11.0 | 4.9 |
| Other assets | 19.7 | 14.3 | 9.0 | 8.0 |
| Liabilities & equity | ||||
| Short-term debt | 5.6 | 5.6 | 3.1 | 2.7 |
| Long-term debt | 15.8 | 19.0 | 11.5 | 13.5 |
| Payables | 11.2 | 4.4 | 3.5 | 3.3 |
| Other liabilities | 28.5 | 20.8 | 13.9 | 11.1 |
| Shareholders' equity | 505.7 | 510.6 | 307.8 | 231.3 |
| Net tangible assets | 505.7 | 510.6 | 307.8 | 231.3 |
4D Molecular Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -109,082,000.0 | -134,585,000.0 | -75,792,000.0 | -86,685,000.0 | — |
| Investing Activities | -92,973,000.0 | -302,437,000.0 | 115,717,000.0 | -17,050,000.0 | — |
| Financing Activities | 112,960,000.0 | 337,250,000.0 | 156,832,000.0 | 3,085,000.0 | — |